{"id":16536,"date":"2025-08-22T11:30:03","date_gmt":"2025-08-22T11:30:03","guid":{"rendered":"https:\/\/www.simpleonlinepharmacy.co.uk\/health-advice\/?p=16536"},"modified":"2025-08-22T11:30:04","modified_gmt":"2025-08-22T11:30:04","slug":"amycretin-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.simpleonlinepharmacy.co.uk\/health-advice\/weight-loss\/amycretin-clinical-trials\/","title":{"rendered":"Amycretin Clinical Trials: What We Know So Far"},"content":{"rendered":"\n

Obesity management medications have become a very popular new treatment option in the worldwide fight against obesity. Since the launch of treatments like Wegovy and Mounjaro, many new weight loss medications have been developed and are making their way to the market.<\/p>\n\n\n\n

One of the latest of these is Novo Nordisk\u2019s Amycretin, a dual-agonist treatment. It works on multiple receptors in your body, offering an enhanced effect over other incretin-based therapies (such as GLP-1 drugs).<\/p>\n\n\n\n

What is Amycretin?<\/h2>\n\n\n\n

After the development of Wegovy, Novo Nordisk began researching multiple new avenues for weight loss medications. Amycretin was one of the first to show promise as a weight loss treatment. Much like Eli Lilly\u2019s Mounjaro, Amycretin is a dual-target weight loss treatment. By affecting multiple receptors in your body, it can offer an enhanced result.<\/p>\n\n\n\n

Its potential as a diabetes treatment has also been investigated. Much like other glucagon-like peptide-1 (GLP-1) medications, Amycretin should allow patients with type 2 diabetes to better control their blood sugar levels.<\/p>\n\n\n\n

Unlike other GLP-1 medications, Amycretin has been tested as both a weekly injection and as an daily oral pill from the early stages of clinical development. By combining Amycretin with SNAC (an absorption enhancer), the drug can be used orally without being digested too quickly.<\/p>\n\n\n\n

How Does Amycretin Work?<\/h2>\n\n\n\n

Amycretin is an amylin agonist and GLP-1 receptor agonist. This means that it fills the same roles as these gut hormones; reducing hunger and slowing digestion.<\/p>\n\n\n\n

Amycretin is a unimolecular treatment; it reacts strongly with both the GLP-1 and amylin receptors in your body. Amylin receptors are responsible for digestion and associated processes. Amycretin, as a dual receptor agonist, benefits from multiple pathways to weight loss, meaning it may produce stronger effects than other treatments.<\/p>\n\n\n\n

What are the Clinical Trial Results?<\/h2>\n\n\n\n

Amycretin has passed Phase 2 clinical trials. <\/p>\n\n\n\n

These first two trials focus on the appropriate dosage and safety concerns around adverse events (side effects and interactions with other health conditions, etc). In both trials, a placebo group was used to make sure the results were significant.<\/p>\n\n\n\n

Phase 1 was conducted over 12 weeks<\/a>, allowing the drug to be tested for safety and tolerability. This first phase focused on the daily oral pill, and on average patients experienced 10% reduced body weight (or 13% when taking a double dose). Phase 2 started to look at the results around the injection variation.<\/p>\n\n\n\n

The results have been promising; in the Phase 2 trials of the injection, patients were observed over 36 weeks, where the highest dose of 60mg produced a weight reduction of up to 24% in patients who were overweight or obese.<\/p>\n\n\n\n

The next step, Phase 3, will focus on the obesity treatment potential. In particular, these trials will help establish the long-term safety profile of the medication. Comprehensive Phase III trials are planned to begin in early 2026. This may be affected by the full results of the Phase 2 trials. <\/p>\n\n\n\n

What are Amycretin\u2019s Side Effects?<\/h2>\n\n\n\n

Currently, we do not have a full list of Amycretin\u2019s potential side effects. Clinical information suggests they will be similar to other weight loss medications. Like other GLP-1 medications, Amycretin\u2019s gastrointestinal side effects may include:<\/p>\n\n\n\n